Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Handa PharmaceuticalsROCO:6620 +1.36%81 EV-to-EBITDA is 26.22 as of Sep. 21, 2026, which is 39% above its 10-year median of 18.86. GuruFocus rates ROCO:6620 with a GF Score™ of 81/100 and a GF Value™ of NT$123.24 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 745 Drug Manufacturers companies, Handa Pharmaceuticals ranks worse than 78.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Handa Pharmaceuticals's enterprise value is NT$20,528 Mil.
Handa Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$783 Mil. Therefore, Handa Pharmaceuticals's EV-to-EBITDA for today is 26.22.
The historical rank and industry rank for Handa Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
ROCO:6620'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -880.29 Med: 18.86 Max: 597.53
Current: 26.27
During the past 12 years, the highest EV-to-EBITDA of Handa Pharmaceuticals was 597.53. The lowest was -880.29. And the median was 18.86.
ROCO:6620's EV-to-EBITDA is ranked worse than 78.79% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.56
vs ROCO:6620: 26.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Handa Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Handa Pharmaceuticals's share price for today is NT$149.00.
Handa Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3.058.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Handa Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Handa Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Handa Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Handa Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Handa Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Handa Pharmaceuticals's EV-to-EBITDA falls into.
Handa Pharmaceuticals's current Enterprise Value is NT$20,528 Mil.
Handa Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$783 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Handa Pharmaceuticals (ROCO:6620) has a EV-to-EBITDA of 26.22 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Handa Pharmaceuticals. This is 39% above median its historical median of 18.86. According to the industry distribution chart, Handa Pharmaceuticals ranks #587 out of 745 companies in the Drug Manufacturers industry, placing it in the top 78.8%.
Is Handa Pharmaceuticals' EV-to-EBITDA too high?
Handa Pharmaceuticals' current EV-to-EBITDA of 26.22 is 39% above median its 10-year median of 18.86. The Drug Manufacturers industry median EV-to-EBITDA is 12.56. Handa Pharmaceuticals' value of 26.22 is 108.8% above this industry median. Based on the distribution chart, Handa Pharmaceuticals ranks #587 out of 745 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Handa Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Handa Pharmaceuticals' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Handa Pharmaceuticals ranks #587 out of 745 companies for EV-to-EBITDA. This places Handa Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.56. Handa Pharmaceuticals' value of 26.22 is 108.8% above this benchmark. While the company's 10-year median is 18.86 vs. the industry median of 12.56, Handa Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.56, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Handa Pharmaceuticals's current EV-to-EBITDA of 26.22 is 108.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Handa Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Handa Pharmaceuticals's current EV-to-EBITDA is 26.22, which is 39% above median its own 10-year median of 18.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Handa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Handa Pharmaceuticals (ROCO:6620) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$123.24, compared to a current price of NT$149.00 — trading 20.9% above its estimated fair value. The current EV-to-EBITDA is 26.22, which is 39% above median its 10-year median of 18.86 and 108.8% above the Drug Manufacturers industry median of 12.56. Handa Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Handa Pharmaceuticals (ROCO:6620), the current EV-to-EBITDA is 26.22 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?
Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$149.00 is trading 20.9% above its estimated GF Value™ of NT$123.24.
GuruFocus considers Handa Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ROCO:6620:
EV-to-EBITDA: 26.22 (39% above median its 10-year median of 18.86)
GF Value™: NT$123.24 vs. price of NT$149.00 (20.9% above fair value)
Industry Position: 108.8% above the Drug Manufacturers median (#587 of 745)
No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
81GF Score
Get the complete analysis for ROCO:6620
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6620 has been successfully added to your 
